Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMIGO: GD2 CAR T-cells for Diffuse Midline Glioma
NCT05544526Phase 1Recruiting
- Sponsor
- University College London
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GD2.CAR-TVS-CTL in diffuse midline glioma (DMG), sponsored by University College London. Primary endpoints: Incidence of grade 3-5 toxicity causally related to the ATIMP at 28 days and Feasibility of manufacturing GD2 CAR T-cells at 28 days. Started Aug 2023; status: recruiting.
02
Drugs
GD2.CAR-TVS-CTL
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT05544526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05544526.